Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661532 | 0.92 | HSD11B1 (0.55) | GPR119FAAHHSD11B1EPHX2MAPT | |
| SCHEMBL31341756 | 0.86 | GPR119 (0.44) | GPR119FAAHHSD11B1EPHX2KDM4E | |
| SCHEMBL10163212 | 0.86 | HSD11B1 (0.49) | GPR119HSD11B1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL12580512 | 0.86 | MAPT (0.46) | GPR119MAPTTHRBKDM4ESMN1; SMN2 | |
| SCHEMBL12506046 | 0.86 | MAPT (0.46) | GPR119MAPTTHRBKDM4ESMN1; SMN2 | |
| SCHEMBL878008 | 0.84 | HDAC4 (0.45) | GPR119MAPTTHRBKDM4ESMN1; SMN2 | |
| SCHEMBL12069832 | 0.84 | EPHX2 (0.51) | GPR119EPHX2MAPTTHRBKDM4E | |
| SCHEMBL20074864 | 0.84 | HDAC4 (0.47) | GPR119MAPTTHRBKDM4ESMN1; SMN2 | |
| SCHEMBL4423384 | 0.81 | GPR119 (0.59) | GPR119SMN1; SMN2 | |
| SCHEMBL14683644 | 0.81 | USP30 (0.49) | HSD11B1MAPTTHRBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | GPR119 366/4885FAAH 1642/4885HSD11B1 1494/4885 |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | DDT, CYP3A43, CYP19A1 | GPR119 1707/4885FAAH 1431/4885HSD11B1 927/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | GPR119 219/4885FAAH 2150/4885HSD11B1 2779/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPR119 136/4885FAAH 1906/4885HSD11B1 17/4885 |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | DDT, CYP3A43, CYP19A1 | GPR119 1707/4885FAAH 1431/4885HSD11B1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.